Allergies & Asthma

It’s no secret that there’s a lot of wasteful spending in healthcare, and patients have become increasingly frustrated by this as their insurance premiums have skyrocketed. Yet unnecessary procedures are still performed every day in the U.S. — and sometimes patients are harmed as a result. MedPage Today‘s Enterprise & Investigative Reporting team needs your
New therapies and devices for chronic obstructive pulmonary disease (COPD) were approved in 2020 and researchers continued to explore expanding the definition of disease beyond spirometry. But 2020 was dominated by the struggles managing the care of highly vulnerable COPD patients during the COVID-19 pandemic. COVID Paradox The delivery of routine components of COPD care,
New guidelines from the National Asthma Education and Prevention Program (NAEPP) of the National Heart, Lung, and Blood Institute (NHLBI) — the agency’s first update since 2007 — take account of new management options including single maintenance and reliever therapy (SMART) and long-acting muscarinic antagonists (LAMAs). As has long been standard practice, the foundation for
Note that some links may require registration or subscription. Pfizer and BioNTech announced emergency authorization from the United Kingdom for their COVID-19 vaccine on Wednesday. Meanwhile, White House Chief of Staff Mark Meadows invited FDA Commissioner Stephen Hahn, MD, to come explain why his agency hasn’t yet granted an emergency use authorization (EUA) for Pfizer’s
Treatment with the investigational anti-IgE biologic ligelizumab was generally effective in patients with H1 antihistamine-unresponsive chronic spontaneous urticaria (CSU) who did not achieve complete symptom control with omalizumab (Xolair), an exploratory analysis of a phase IIb extension study showed. In a subset of omalizumab-treated patients with a score greater than 0 on the 7-day urticaria
Patients with cancer and COVID-19 have a higher risk of severe disease and mortality, researchers reported. Of 89 cancer patients admitted to the intensive care unit (ICU) due to COVID-19, 32 died, a mortality rate of 36%, reported Michael Dang, MD, a critical care fellow at Memorial Sloan Kettering Cancer Center in New York City,